Has nanotechnology failed cancer patients?

Negative news abounded for cancer based nanotechnologies in 2016. From the outside, it might appear that its promise has faded. The reality is far from the truth. Like many great endeavors, past failures are shining a bright light on the path forward.

2017: Prognosticating Progress in Cancer Cures and Costs

2016 continued the trend of pharmaceutical companies filling their cancer therapy pipelines and investing significant capital in their oncology research and development programs. Despite this, and aside from a few well-polished product commercials, the industry had little new to celebrate at the end of 2016. Checkpoint inhibitors built on their previous successes, but have also begun to show their weaknesses. Revenue grew from a few “blockbuster,”